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Abstract Funiculosin, a center N inhibitor of the bc, complex, induces a blue-shift in the cytochrome b spectrum. A thermosensitive revertant 
[Coppee, J.Y. et al., J. Biol. Chem. 269 (1994) 422142261 isolated from a cytochrome b respiratory-deficient mutant, exhibits a red-shift instead of 
the blue-shift retained in the original mutant and shows resistance to this inhibitor. Replacing cytochrome b-Asparagine-208 by Lysine in this 
revertant, keeping the original mutation S206L, leads, when mitochondria are incubated at non-permissive temperature, to complete loss of bc, 
complex activity and funiculosin-binding, while the antimycin-binding is conserved. These data suggest some inhibitor site specificity and close 
proximity between the funiculosin-binding site and the catalytic center N domain (QN). 
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1. Introduction 
The role of the bc, complexes in the electron transfer coupled 
to proton translocation across the membrane has been best 
described to date by the widely accepted Q-cycle scheme intro- 
duced by Mitchell [l] and reviewed by Trumpower [2]. This 
mechanism requires two distinct quinone reaction sites, the 
hydroquinone oxidation (QP) and the quinone reduction (QN) 
centers, which are located on opposite sides of the membrane. 
Two classes of inhibitors are linked to each of these centers: one 
set of compounds, exemplified by myxothiazol and reviewed by 
Link et al. [3], blocks the electron transfer through the QP side; 
another set of inhibitors, exemplified by antimycin blocks the 
QN center. 
Cytochrome b is the only subunit of the bc, complex which 
is coded by mitochondrial DNA. The first folding model for 
cytochrome b was proposed by Widger et al. [4] and Saraste [5]. 
Knowledge about drug-resistance mutations (reviewed in [6]) 
has suggested, on the basis of other calculations, a modified 
version of this model with eight instead of nine hydrophobic 
helices spanning the inner mitochondrial membrane [7-91. This 
revised model fits all the available data on mutants, in particu- 
lar the assignment of the axial ligands to cytochrome b,,, (bH) 
in the vicinity of the QN center, and to cytochrome b,,, (bJ in 
the vicinity of the QP center [lo,1 11. 
The bc, complex inhibitors have strong effects on the spectra 
of the heme close to the respective binding sites and minor 
effects on the distant heme [12]. For instance, the center N 
*Corresponding author. Fax: (33) 91 76 03 59. 
Abbreviations: QN center, ubiquinone reduction center of the mitochon- 
drial ubiquinol cytochrome c oxidoreductase (cytochrome bc, complex 
or complex III) on the negative side of the inner mitochondrial mem- 
brane; Qp center, ubiquinol oxidation center of ubiquinol cytochrome 
c oxidoreductase on the positive side of the inner mitochondrial mem- 
brane; DBH,, decylubiquinol (2,3-dimethoxy-S-methyl-6-decyl-1,4- 
benzoquinol); Me,SO, dimethyl sulfoxide. Enzyme: Ubiquinol cyto- 
chrome c oxidoreductase: EC 1.10.2.2. (bc, complex). 
inhibitors antimycin and funiculosin have been found spectro- 
scopically and potentiometrically to affect mainly heme bu [ 121, 
while myxothiazol and stigmatellin affect heme b, [13,14]. 
These inhibitors induce a spectral shift of the cytochrome b 
hemes, generally a red-shift (bathochromic effect), which, ac- 
cording to Link et al. [3] is proportional to the amount of bound 
inhibitor. These effects on the optical spectra have previously 
been observed on the three absorption bands (a, p, y) of both 
oxidized and reduced cytochrome b in submitochondrial parti- 
cles and bc, complex of beef-heart by Kamenskii et al. [15]. 
These authors described a red-shift with antimycin and a blue- 
shift with funiculosin. 
We report here the spectral shifts caused by these two inhib- 
itors in reduced cytochrome b of the wild-type strain and in a 
cytochrome b respiratory-deficient mutant, and the striking 
modifications observed with a thermosensitive revertant modi- 
fied in the vicinity of heme b,,,. These results yield some new 
insights on the QN center. 
2. Materials aud methods 
2.1. Strains 
The wild-type strains and the original mutants were from the Gif 
collection. 
Parental strain (wild-type box’): the diploid KM91 was obtained by 
crossing 777-3A a adel opl rho’ mit+ with KLl44A a his1 trpl OPl 
rho”. The original rho+ mit- respiratory-deficient mutant 777-3A/ 
M4721 was isolated from the haploid strain 777-3A a adel opl rho+ 
mit+ [16] and the mutation was mapped within the cytochrome b gene 
[1 11. The haploid strain 777-3A/M4721 was crossed with KL144A a 
his1 trpl OPI rho” to form the diploid KM 208. Its mt DNA sequence 
has been determined and a single missence mutation S206L has been 
identified [1 I]. The respiratory competent revertant S206LN208K has 
been selected from the respiratory-deficient S206L (KM208) [17]. The 
experiments were carried out with the diploid strains, which are all 
isogenic except for the cytochrome b mutations. 
Similarly, the original rho+ mit- respiratory deficient mutant 777-3A1 
M4410 was isolated from the haploid strain 777-3A [16] and the muta- 
tion mapped within the cytochrome b gene [1 11. This strain was crossed 
with ILl26lC/52 a w-al OPI rho” to form the diploid PS493 and a 
single mutation M22lK has been identified [ll]. The parental strain 
(box’) obtained using the same protocol was named PS409. 
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2.2. Media, growth conditions, preparation of mitochondria and 
cytochrome content determination 
They were as described in ref. [IS]. Mitochondria were used without 
adding any detergent so as to preserve the membrane integrity. 
MR3 buffer: 0.65 M Sorbitol, 10 mM KH,PO,, 2 mM EDTA, 0.1 
mM MgCl,, 0.3% BSA, pH 6.5. 
2.3. Shzft measurements 
Red- or blue-shift spectra were recorded in an Amino-DW2A spec- 
trophotometer as the spectral difference between the dithionite reduced 
enzyme with and without a saturating amount of inhibitor. The wave- 
lengths were calibrated with a Holmium filter. Mitochondria were first 
reduced by adding a few grains of sodium dithionite and the base line 
was recorded. Inhibitor was then added to the sample cuvette and the 
same volume of solvent to the reference cuvette. The spectra were 
recorded at 25°C in the MR3 buffer. 
2.4. be, complex activity and inhibitor titration 
DBH,-cytochrome c reductase activity was determined spectro- 
photometrically [19] in isolated mitochondria by measuring the reduc- 
tion of cytochrome c(40pM) with the dual wavelength-stirred reaction 
cuvette procedure at 550 nm using 540 nm as a reference. The reaction 
was observed at 25°C in a phosphate buffer (50 mM phosphate-K, 50 
PM EDTA, pH 7.4), in the presence of 2 mM KCN with a synthetic 
analog of ubiquinol (100 PM), decylubiquinol (2,3-dimethoxy-5- 
methyl-6-decyl-1,Cbenzoquinol) as electron donor. The slight chemical 
reduction of cytochrome c which occurred with decylubiquinol in the 
absence of mitochondria was substracted from the enzymatic assay with 
mitochondria. 
The I,, values for inhibitors, defined as the concentration required 
to reduce the decylubiquinol cytochrome c reductase activity by 50%, 
were deduced from the inhibitor titration curves obtained at increasing 
concentrations of each inhibitor. With each aliquot of mitochondria, 
the inhibitor was incubated for 3 min before the measurement was 
performed, as that it could penetrate into the membrane. Iso was calcu- 
lated in moles of inhibitor per mole of cytochrome b by measuring the 
spectral cytochrome b content in each strain (not shown; as in ref [l 11). 
In each strain the relative inhibitor titer (I,,), has been taken to be the 
ratio between I,, with the mutated strain and I,, with the wild type 
strain. This parameter indicates the resistance of the strain to the inhib- 
itor, in comparison with the wild type strain. 
2.5. Chemicals 
Inhibitors were used in the form of stock ethanolic or Me,SO solu- 
tions. Antimycin and decylubiquinone were from Sigma, myxothiazol 
from Boehringer and funiculosin was a generous gift from Sandoz 
Laboratory. 
3. Results 
3.1. General characteristics of the strains 
The cytochrome b mutant S206L did not grow on non-fer- 
mentable substrates (glycerol, ethanol, . ..) but continued to 
show a low bc, complex activity, while the antimycin binding 
site was not modified [l 11. This mutation in position 206 was 
localized at the edge of the transmembrane a-helix IV, at the 
beginning of the extramembranous loop between a-helices IV 
and V (matrix side). A thermosensitive revertant S206L- 
N208K has been selected from this mutant, which recovered 
respiratory growth and shows efficient respiratory activities 
1171. 
ANTIMYCIN FUN~CULOSIN 
Fig. 1. Spectral shift of reduced cytochrome b induced by the binding of two center N inhibitors in the wild type strain, a cytochrome b 
respiratory-deficient mutant and a revertant. The sample and reference cuvettes were reduced with dithionite. The broken line indicates the difference 
spectra without any added inhibitor; the inhibitor was added to the sample cuvette in saturating amounts in relation to the cytochrome b content 
(10 PM with antimycin, 20 PM with funiculosin) and the same volume of solvant was placed in the reference cuvette. In each strain, the intensity 
of the shift is dependent on the cytochrome b content. The strains were: (a) wild type BOX’, (b) revertant S206L-N208K and (c) original cytochrome 
b mutant S206L. Cytochrome b content - in antimycin assays: BOX’, 0.95 nmoUm1; S206LN208K, 1.13 nmole/ml; S206L, 0.89 nmohml; in 
funiculosin assays: BOX’, 0.84 nmohml; S206L-N208K, 0.9 nmollml; S206L, 0.89 nmoYm1. 
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Fig. 2. Inhibition of the DBH, cytochrome c reductase activity by 
funiculosin and antimycin. The activity was measured in the dual wave- 
length mode at 55&540 nm at 25°C in a stirred cuvette; 100% activity 
was 77 s-’ and 53 s-’ with the wild type and revertant, respectively. 
(A) The inhibitor titer I,, with antimycin was 0.39 mol antimycin/mol 
cytochrome b, in the case of the wild type strain. The relative inhibitor 
titer (Iso), with the revertant (I,, revertant&, wild type) was 0.95 in the 
case of antimycin. (B) The inhibitor titer I,, with funiculosin was 8.4 
mol of funiculosin per mole of cytochrome b,,, in the case of the wild 
type strain. The relative inhibitor titer with the revertant was 7.5 in the 
case of funiculosin. 
Like mutant S206L, the cytochrome b mutant M221K did 
not grow on respiratory substrates. This strain synthesized a 
cytochrome b content which was about 70-80% that of its 
parental strain (box’), but did not retain bc, complex activity 
[20]. However, no subunit of its bc, complex was found to be 
missing, as shown by the electrophoretic profile of the isolated 
complex [ 191. 
3.2. Red- or blue-shift spectra 
With the parental strain KM91, the difference spectra ob- 
served after adding saturating amounts of antimycin or funicu- 
losin to the reduced mitochondria were similar in shape to those 
previously observed in the a and y absorption bands of bovine 
heart cytochrome b [15,21]. These S-shaped curves crossed the 
baseline at 562 nm in the case of the a-band and 430 nm in the 
case of the y-band. The spectrum recorded after adding antimy- 
tin had a minimum at 425 (y-band) and 559 mu (a-band) and 
a maximum at 434 nm and 565 nm: this long wave maximum 
was interpreted as reflecting a shift of cytochrome b,,, toward 
longer wavelengths (bathochromic effect). As the Soret bands 
were by far the most intense and as they were reproducible, they 
were used in this study in order to compare the action of the 
inhibitors with the various strains. After adding funiculosin, the 
spectrum was a mirror-image of that observed in the presence 
of antimycin, with a short wavelength shift of the b,,, spectrum 
(hypsochromic effect) (Fig. la). Similar results were obtained 
with the cytochrome b respiratory-deficient mutant S206L, ex- 
cept that the maximum and the middle point were displaced 
towards the red by about 1.5 nm, which is in agreement with 
the fact that heme b,,, in this mutant is selectively shifted in the 
same way by 1.5 nm [ll] (Fig. lc). Antimycin had the same 
effect on the revertant S206L-N208K, as on the wild type and 
mutant, namely a red-shift of cytochrome b, while a different 
situation occurred with funiculosin: instead of the usual blue- 
shift generated by this inhibitor, a red-shift was observed in this 
double mutated strain (Fig. lb). As the mutation S206L alone 
in the original mutant did not modify the type of action of 
funiculosin on the cytochrome b spectra, this spectral change 
from an hypsochromic to a bathochromic effect is attributed 
to the replacement of asparagine 208 by lysine in addition to 
the original mutation. 
3.3. Inhibitor titrations of wild-type and revertant 
The inhibitory action of antimycin and funiculosin at the bc, 
complex level was illustrated by Fig. 2. From these curves, the 
I,, values were determined as described in section 2.4. The 
relative inhibitor titer with the revertant S206L-N208K was 
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Fig. 3. Effect of incubation at a non permissive temperature (37‘C) on 
the complex III activity of mitochondria isolated from wild type and 
thermosensitive revertant cells grown at a permissive temperature 
(28’C). The DBH2 cytochrome c reductase activity was measured at 
37°C; 100% activity was 128 s-’ with the wild type BOX’ and 70 s-l 
with the revertant. The t: (50% activity decrease) was 1 h 10 min in the 
case of the thermosensitive strain S206LN208K. 
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Fig. 4. Effect of incubation at a non-permissive temperature (37°C) on 
the cytochrome spectra. Difference spectra of mitochondria were re- 
corded in the split mode between 500 and 650 nm before (A) and after 
(B) incubation for 6 h at 37°C. The sample cuvette was reduced with 
dithionite and the reference cuvette was oxidized with ferricyanide. 
Mitochondria of the wild type strain BOX’ and of the revertant S206L- 
N208K were suspended at 1 mg/ml in the MR3 buffer. Spectral cyto- 
chrome b content: (A) before incubation: 0.38 nmol/ml with BOX+; 0.35 
nmoYm1 with the revertant S206L-N208K; (B) after incubation: 0.34 
nmoYm1 with BOX’; 0.31 nmol/ml with the revertant S206LN208K. 
found to be equal to 1 with antimycin and 7.5 with funiculosin. 
These values reflect the resistance of this revertant towards the 
inhibitors, directly evaluated at the bc, complex level: no resis- 
tance was observed with antimycin and about 7-fold more resis- 
tance than with the wild-type was shown with funiculosin. 
3.4. Thermosensitivity of cytochrome bc, complex activity in 
mitochondria of the revertant 
The growth of the thermosensitive revertant S206L-N208K 
on the respiratory substrates (ethanol or glycerol) is abolished 
at 37°C. Mitochondria were isolated from the wild type yeast 
(box’) and the revertant cells grown at permissive temperature 
(28°C) on galactose medium. Under these conditions, the rever- 
tant synthesized a cytochrome b content which was quasi-iden- 
tical to that of the wild-type, (about 90%) and exhibited the 
same growth yield [17]. 
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To determine whether the activity of the be, complex is af- 
fected by the temperature when the cells are grown at their 
permissive temperature (28”C), (i.e. under the conditions where 
the complex is functional), the DBH,-cytochrome c reductase 
activity was measured as a function of the incubation time at 
a non-permissive temperature (37°C). As shown in Fig. 3, the 
in vitro bc, complex activity of the wild-type was quite stable, 
while the mitochondria of the revertant are susceptible to be 
inactivated at the high temperature: all the activity was abol- 
ished after exposure of the mitochondria from this strain at 
37°C for 4 h (Fig. 3). 
In order to check whether the cytochrome b heme is still 
present in that strain when the activity has been abolished, the 
difference spectrum of mitochondria of the revertant and that 
of the wild-type strain were recorded (dithionite reduced versus 
oxidized samples), before and after exposure for 6 h at 37°C 
(Fig. 4). No or slight decrease (about 10% as in Fig.4) in the 
spectral cytochrome b was observed with both strains, and the 
ratio of cytochrome b content with the revertant to that with 
the parental strain remained to be about 90% after like before 
the incubation: this means that incubation at the non-permis- 
sive temperature does not affect the attachment of cytochrome 
b heme. In the same way, the various subunits of the bc, com- 
plex were still present (G. Brasseur, P. Brivet-Chevillotte article 
in preparation). 
3.5. Thermosensitivity of the two center N inhibitor binding to 
the bc, complex 
Blue- or red-shifts induced by the inhibitors reflect their 
binding to cytochrome b. They were always determined in this 
study at saturating concentration of inhibitor (while a titration 
curve would require lower amounts of inhibitor [22]). As it was 
confirmed that cytochrome b heme is still present after aboli- 
tion of the bc, complex activity in the revertant, it was possible 
to qualitatively test the binding of the inhibitors depending on 
whether or not the shift occurred, after incubation at the non- 
permissive temperature and by making comparisons with the 
wild type strain. After exposure for 5 h at 37°C the red-shift 
resulting from antimycin binding was observed in the revertant 
as well as in the wild-type mitochondria (Fig. 5). On the other 
hand, the (red) shift observed with funiculosin completely dis- 
appeared in the revertant, while the blue-shift persisted in the 
wild-type mitochondria (Fig. 5). These data therefore suggest 
that antimycin binding is not strongly modified in the revertant, 
while funiculosin binding seems to be abolished, as is the 
Table 1 
Summary of the bc, complex activity and inhibitor binding observed 
after incubating mitochondria isolated from the wild type strain and the 
thermosensitive r vertant for 5 h at 37°C 
Strains DBH2-Cyt-c Funiculosin Antimycin Myxothiazol 
reductase binding binding binding 
activity (shift) (shift) (shift) 
Wild type + + + + 
S206L-N208K - - + + 
The DBH, cytochrome c reductase activity was measured as in Fig. 2. 
As the intensity of the spectral shift is generally proportional to the 
bound inhibitor [3], the inhibitor binding was estimated epending on 
whether or not the shift was induced in cytochrome b after incubation 
at non-permissive temperature, as in Fig. 5. 
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Fig. 5. Spectral shift of reduced cytochrome b induced by the binding of antimycin or funiculosin in the wild type and thermosensitive revertant 
mitochondria, incubated for 5 h at 37°C. Conditions were as in Fig. 1, except that the mitochondria were incubated for 5 h in the MR3 buffer at 
37’C. Wild type strain = BOX+; cytochrome b revertant = S206LN208K. Cytochrome b content - in antimycin assays: BOX’, 1.16 nmol/ml; 
S206L-N208K, 1.53 nmol/ml; in funiculosin assays - BOX’, 1.37 nmol/ml; S206L-N208K, 0.94 nmol/ml. 
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bc, complex activity, after incubation at non-permissive tem- 
perature. These results are summarized in Table 1. 
3.6. Another case: mutant M221K 
In this strain, the replacement of methionine by lysine which 
did not pertub a correct assembly of the bc, complex, induced 
the loss of electron transfer through this complex. Unlike what 
occured with the revertant S206L-N208K, the antimycin bind- 
ing was strongly affected [20], since the dissociation constant 
(as measured by fluorescence) increased from about lO_” M 
with the wild type, to about 10m3 M with this mutant. With a 
large excess of inhibitor a (diminished) red-shift was still ob- 
served however with antimycin, while the spectral blue-shift 
induced by funiculosin in the wild type strain completely disap- 
peared in that mutant (Fig. 6). So in this center N mutant, like 
in the thermosensitive inactivated center N revertant S206L- 
N208K, a concomitant loss of activity and of the shift due to 
the funiculosin binding was observed. On the other hand, the 
center P inhibitor myxothiazol induced an identical red-shift in 
both strains (not shown). 
4. Discussion 
With the revertant S206L-N208K, a red-shift of cytochrome 
b,,, heme was induced by saturating amounts of funiculosin 
instead of the blue-shift usually observed with the wild type 
species: this switch from a hypsochromic to a bathochromic 
effect reflects a considerable change in the electronic surround- 
ings of heme b,,,, and in the binding niche of funiculosin. As 
the original mutant S206L like the wild type strain, exhibits a 
blue-shift, this reversal of the shift direction must have been due 
to the addition of a second mutation whereby asparagine 208 
was replaced by a charged lysine. A similar change from a blue 
to a red-shift was also observed (unpublished results) with 
another proximal revertant isolated from mutant S206L [17], 
namely S206L-N208Y and with a distal one S206GW3OC; but 
the strain constructed with the single mutation W3OC [17] ex- 
hibits a blue-shift and has wild type characteristics (data not 
shown). These data suggest hat the nature of the effect induced 
by funiculosin (hypso or bathochromic) is depending on the 
interraction of a second mutation with the original S206L mu- 
tation. One common feature between these three reversions is 
that they have either a hydrophylic amino-acid in replacement 
of a hydrophobic one in position 30 (W3OC) or a bulkier one 
in position 208 (N208K or N208Y): this second mutated amino 
acid might compensate the loss of the well-conserved hydro- 
phylic amino acid serine in the original mutant S206L and 
allows restoration of bc, complex activity [17]; it also confers 
thermosensitivity to the revertant and the observed red-shift 
with funiculosin. With antimycin on the contrary, no change 
is observed in the (red) shift induced by this inhibitor with the 
revertant S206LN208K (or with any of the other strains 
tested). 
From the titration curves of the two inhibitors at the complex 
III level, it was deduced that the revertant S206GN208K be- 
haves like the wild type strain in response to antimycin 
((I&, = 1) but is resistant to funiculosin ((Is& = 7). No resis- 
tance to either antimycin [l l] or funiculosin has been found to 
occur with the original mutant S206L, while a resistance to 
funiculosin was observed with another revertant of this mutant, 
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Fig. 6. Spectral shifts of dithionite reduced cytochrome b induced by 
antimycin and funiculosin binding in the wild type BOX’ and the 
cytochrome b respiratory-deficient mutant M221K. The antibiotics 
were added at saturating level: 5 PM antimycin and 20 ,uM funiculosin. 
Cytochrome b,,, content of each strain: 1.2 nmol/ml. 
namely S206GN208Y [23]. The replacement of asparagine 208 
by either lysine or tyrosine specifically alters the funiculosin 
binding. These data confirm the involvement of asparagine 208 
in funiculosin binding site. 
A long incubation of the thermosensitive revertant at non- 
permissive temperature leads to the inactivation of the bc, com- 
plex activity (Fig. 3), and this inactivation shows up particularly 
clearly in the reduction kinetics of cytochrome b by the center 
N pathway (Brasseur G. and Brivet-Chevillotte P., article in 
preparation). Under these conditions, the red-shift induced by 
saturating amounts of either antimycin (Fig. 5) or the center P 
inhibitor myxothiazol (data not shown) was not strongly af- 
fected, so that it can be assumed, that these inhibitors still bind 
to cytochrome b. The shift induced by funiculosin completely 
disappeared on the contrary in the revertant S206L-N208K, so 
that it might be concluded that the structural perturbation of 
the tertiary structure induced by incubation at non-permissive 
temperature involved not only the loss of bc, complex activity 
but also seems to abolish the funiculosin binding. An almost 
similar situation with the concomitant loss of activity (due to 
center N modification) and likely funiculosin binding has been 
observed with the cytochrome b respiratory-deficient mutant 
M221K (Fig. 6). 
In addition to showing that asparagine 208 and methionine 
221 are involved in the funiculosin binding site, these data taken 
as a whole suggest hat: 
(i) At least part of the funiculosin binding site is very close to 
the b,, heme. This is in agreement with the first location of a 
funiculosin resistance mutation in yeast, which was found to be 
L198F [24]. Moreover, Degli Esposti et al. [25] hypothesized 
that position 194 might be involved in funiculosin binding be- 
cause in the horse, which is naturally resistant to funiculosin, 
alaninel94 is replaced by valine. These two positions (194, 198) 
are close to histidine197 linking the b,,, heme to the transmem- 
brane helix IV. Besides, funiculosin is the only bc, inhibitor 
which has been found to induce a large shift on the midpoint 
potential of heme 562 (by about 100 mV [12]); this might be 
explained by the close proximity of its binding site with this 
heme. 
(ii) The antimycin andfuniculosin binding sites partly overlap 
but are not identical. Indeed, co-resistance to these two inhib- 
itors has been identified so far only in position G37 with M. 
musculus [26], Paramecium [27], S. cerevisiae [28] and S. pombe 
(A37) [29], in position M221 in yeast (mutant M221K described 
above) and in position G232 in the mouse [30]. The amino-acid 
in the latter position is not conserved and threonine is present 
instead of glycine in yeast. These two areas (37 and 221-232) 
are neighbouring ones within the 3D structure of the protein 
[17]. No antimycin resistance were observed in the 197-208 
region, where funiculosin resistant mutants have been identified 
[23,24]. 
(iii) The finiculosin binding site is in the close vicinity of the 
catalytic center N site. Center N inhibitors block cytochrome 
b,, heme oxydation by quinone species in the steady-state 
electron transfer. With the thermosensitive revertant incubated 
at non-permissive temperature, mutations in positions 206 and 
208 located at the edge or even inside transmembranous helix 
IV might initially favour a local distorsion of the tertiary struc- 
ture of cytochrome b and probably increase the distance inside 
and/or between the helices, so that the electron transfer is 
blocked and/or the quinone binding site affected. Due to its 
location (at 610A from the N-side protein [31]) and to its 
sensitivity to antimycin, the EPR-detectable semiquinone Q’i- 
(or Q’n-) binding site might be close to the antimycin binding 
site which was estimated to be 17 A from cytochrome bs6* heme 
[32]; this heme b562 was established to be located approximately 
in the middle of the membrane (estimated to be 40-50 A in 
width) [33]. Rich et al. [12] hypothesized that this EPR-detect- 
able Q’ii might be linked to the reduced form of cytochrome 
b,,,, while other redox form of EPR-silent ubiquinone species 
might be present at the QN site and interract with heme b,,,, as 
previously suggested by Salerno et al. [34]. The funiculosin 
binding site spread over from the close vicinity of heme b,,, to 
the antimycin binding site (near positions 221-232). The con- 
comitant loss of the bc, complex activity (due to perturbation 
in the center N side either near position 208 or 221) and of the 
shift induced by the binding of funiculosin (suggesting loss or 
drastic perturbation of this binding) strongly suggest he close 
G. Brasseur, I? Brivet-CheviNottelFEBS Letters 354 (1994) 23-29 
proximity between the funiculosin binding site and the catalytic 
center N domain. 
Acknowledgements: Wethank Sandoz Laboratory for the generous gift 
of funiculosin and Jessica Blanc for looking over the English. 
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